Immuni T

Immuni T, a CRO company founded in 2005, specializes in providing services for biotherapeutics and immunomodulators at competitive rates. The company's expertise lies in customized cell-based assays, flow cytometry, and ELISA assays in bioanalysis in GLP/GCLP regulated laboratories. Immuni T has developed an ex vivo method for evaluating the immunogenic potential of new biotherapeutics and biosimilars, which involves assessing freshly-collected PBMC from multiple donors. This method offers a rapid and cost-effective means for evaluating the immunogenic potential of a molecule in a human system. Additionally, Immuni T conducts the development and validation of immunogenicity methods and ligand-binding assays for PK analysis for both pre-clinical and clinical programs. Furthermore, the company offers functional customized cell-based assays such as cytotoxicity assays and other assays like Treg or NK functional assays. Immuni T performs human ex-vivo immunogenicity prediction/comparison assays for new biotherapeutics, immunogenicity tests for biotherapeutics in clinical development, ligand-binding assays for the quantification/detection of peptides, proteins, or nucleic acids, immuno assays based on flow cytometry analysis, and multiplex analysis on Luminex. All these services are provided with customization, development, and validation of assays for pre-clinical and clinical studies. As a startup operating in the Analytics, Biotechnology, and Pharmaceutical industries, Immuni T positions itself as a valuable partner for companies in the biopharmaceutical sector seeking comprehensive and specialized services for the development and evaluation of biotherapeutics and immunomodulators.